Quarterly report pursuant to Section 13 or 15(d)

Organization and Summary of Significant Accounting Policies - Additional Information (Detail)

v3.22.1
Organization and Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Organization And Summary Of Significant Accounting Policies [Line Items]    
Cash, cash equivalents, and marketable securities $ 124.5  
ASU No. 2021-10    
Organization And Summary Of Significant Accounting Policies [Line Items]    
Change in Accounting Principle, Accounting Standards Update, Adopted [true false] true  
Change in Accounting Principle, Accounting Standards Update, Adoption Date Jan. 01, 2022  
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false] true  
Revenue | Concentration of Credit Risk and Other Risks and Uncertainties | Vertex Pharmaceuticals Inc    
Organization And Summary Of Significant Accounting Policies [Line Items]    
Percentage of total revenues 0.00% 63.00%
Revenue | Concentration of Credit Risk and Other Risks and Uncertainties | Takeda Pharmaceuticals Inc    
Organization And Summary Of Significant Accounting Policies [Line Items]    
Percentage of total revenues 30.00% 7.00%
Revenue | Concentration of Credit Risk and Other Risks and Uncertainties | BMS    
Organization And Summary Of Significant Accounting Policies [Line Items]    
Percentage of total revenues 70.00% 30.00%
Other Assets    
Organization And Summary Of Significant Accounting Policies [Line Items]    
Restricted cash $ 2.7